QQQ   348.10 (-0.54%)
AAPL   179.06 (+0.99%)
MSFT   330.49 (-0.22%)
META   263.54 (+0.39%)
GOOGL   123.29 (-0.31%)
AMZN   120.26 (-1.15%)
TSLA   200.41 (-0.37%)
NVDA   386.18 (-3.72%)
NIO   7.38 (-0.40%)
BABA   79.43 (+0.97%)
AMD   120.40 (-3.89%)
T   15.79 (+0.96%)
F   12.07 (-4.13%)
MU   68.52 (-4.42%)
CGC   0.82 (-3.68%)
GE   101.02 (-1.35%)
DIS   87.98 (+0.18%)
AMC   4.48 (-3.24%)
PFE   37.90 (+2.40%)
PYPL   61.89 (-0.26%)
NFLX   395.60 (+0.67%)
QQQ   348.10 (-0.54%)
AAPL   179.06 (+0.99%)
MSFT   330.49 (-0.22%)
META   263.54 (+0.39%)
GOOGL   123.29 (-0.31%)
AMZN   120.26 (-1.15%)
TSLA   200.41 (-0.37%)
NVDA   386.18 (-3.72%)
NIO   7.38 (-0.40%)
BABA   79.43 (+0.97%)
AMD   120.40 (-3.89%)
T   15.79 (+0.96%)
F   12.07 (-4.13%)
MU   68.52 (-4.42%)
CGC   0.82 (-3.68%)
GE   101.02 (-1.35%)
DIS   87.98 (+0.18%)
AMC   4.48 (-3.24%)
PFE   37.90 (+2.40%)
PYPL   61.89 (-0.26%)
NFLX   395.60 (+0.67%)
QQQ   348.10 (-0.54%)
AAPL   179.06 (+0.99%)
MSFT   330.49 (-0.22%)
META   263.54 (+0.39%)
GOOGL   123.29 (-0.31%)
AMZN   120.26 (-1.15%)
TSLA   200.41 (-0.37%)
NVDA   386.18 (-3.72%)
NIO   7.38 (-0.40%)
BABA   79.43 (+0.97%)
AMD   120.40 (-3.89%)
T   15.79 (+0.96%)
F   12.07 (-4.13%)
MU   68.52 (-4.42%)
CGC   0.82 (-3.68%)
GE   101.02 (-1.35%)
DIS   87.98 (+0.18%)
AMC   4.48 (-3.24%)
PFE   37.90 (+2.40%)
PYPL   61.89 (-0.26%)
NFLX   395.60 (+0.67%)
QQQ   348.10 (-0.54%)
AAPL   179.06 (+0.99%)
MSFT   330.49 (-0.22%)
META   263.54 (+0.39%)
GOOGL   123.29 (-0.31%)
AMZN   120.26 (-1.15%)
TSLA   200.41 (-0.37%)
NVDA   386.18 (-3.72%)
NIO   7.38 (-0.40%)
BABA   79.43 (+0.97%)
AMD   120.40 (-3.89%)
T   15.79 (+0.96%)
F   12.07 (-4.13%)
MU   68.52 (-4.42%)
CGC   0.82 (-3.68%)
GE   101.02 (-1.35%)
DIS   87.98 (+0.18%)
AMC   4.48 (-3.24%)
PFE   37.90 (+2.40%)
PYPL   61.89 (-0.26%)
NFLX   395.60 (+0.67%)
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

$36.73
-0.37 (-1.00%)
(As of 02:53 PM ET)
Compare
Today's Range
$35.76
$38.21
50-Day Range
$36.54
$49.49
52-Week Range
$35.70
$101.30
Volume
604,008 shs
Average Volume
1.10 million shs
Market Capitalization
$2.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.93

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
112.4% Upside
$76.93 Price Target
Short Interest
Healthy
11.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
-0.02mentions of Mirati Therapeutics in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$28,035 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($12.66) to ($11.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

515th out of 1,006 stocks

Pharmaceutical Preparations Industry

247th out of 492 stocks


MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Barclays Remains a Buy on Mirati Therapeutics (MRTX)
Analyst Expectations for Mirati Therapeutics's Future
Mirati Therapeutics (MRTX) Receives a Buy from JMP Securities
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
5/09/2023
Today
5/31/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$76.93
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+113.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-740,870,000.00
Net Margins
-3,901.06%
Pretax Margin
-3,898.38%

Debt

Sales & Book Value

Annual Sales
$12.44 million
Book Value
$14.82 per share

Miscellaneous

Free Float
56,290,000
Market Cap
$2.10 billion
Optionable
Optionable
Beta
1.04

Social Links


Key Executives

  • David D. Meek
    Chief Executive Officer & Director
  • Charles M. BaumCharles M. Baum
    President, Director & Head-Research & Development
  • Laurie D. Stelzer
    Chief Financial Officer
  • James G. ChristensenJames G. Christensen
    Chief Scientific Officer
  • Alan Bart Sandler
    Chief Medical Officer & Executive Vice President













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

12 brokerages have issued 1-year price targets for Mirati Therapeutics' stock. Their MRTX share price forecasts range from $40.00 to $188.00. On average, they expect the company's stock price to reach $76.93 in the next twelve months. This suggests a possible upside of 113.1% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2023?

Mirati Therapeutics' stock was trading at $45.31 at the beginning of the year. Since then, MRTX shares have decreased by 20.3% and is now trading at $36.10.
View the best growth stocks for 2023 here
.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 6,760,000 shares, a decline of 14.8% from the April 30th total of 7,930,000 shares. Based on an average daily trading volume, of 981,200 shares, the days-to-cover ratio is currently 6.9 days.
View Mirati Therapeutics' Short Interest
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its quarterly earnings data on Tuesday, May, 9th. The biotechnology company reported ($3.18) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.29. The biotechnology company had revenue of $7.17 million for the quarter, compared to analyst estimates of $4.80 million. Mirati Therapeutics had a negative trailing twelve-month return on equity of 71.90% and a negative net margin of 3,901.06%. Mirati Therapeutics's quarterly revenue was up 910.9% compared to the same quarter last year. During the same quarter last year, the business posted ($3.40) EPS.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.35%), BlackRock Inc. (5.57%), Wellington Management Group LLP (4.64%), State Street Corp (3.97%), Price T Rowe Associates Inc. MD (3.04%) and Perceptive Advisors LLC (2.71%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $36.10.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.10 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.96) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 413 workers across the globe.

Does Mirati Therapeutics have any subsidiaries?
The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -